Summary & Overview
HCPCS A2032: Myriad Matrix, Per Square Centimeter (Add-on)
HCPCS Level II code A2032 denotes billing for a myriad matrix product invoiced per square centimeter as an add-on supply to a primary procedure. This code is used when a biologic or synthetic matrix is applied to a wound or surgical site and must be listed separately in addition to the primary procedure code. Nationally, add-on supply codes like A2032 matter because they affect facility and professional reimbursements for advanced wound-care materials and help standardize reporting of product-based resource use.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of the matrix, typical sites of service where the product is applied, and how the code is positioned as an add-on supply. The publication also outlines expected content such as billing benchmarks, payer coverage tendencies, and relevant policy considerations that influence coverage and payment for per-square-centimeter wound matrices.
This summary equips clinicians, billing professionals, and policy analysts with a clear understanding of what A2032 represents, the settings where it is typically used, and the types of reimbursement and documentation topics to examine when managing claims that include this add-on supply code.
Billing Code Overview
HCPCS Level II code A2032 describes myriad matrix, per square centimeter (add-on, list separately in addition to primary procedure). This code represents billing for a specialized wound matrix product measured and billed by the square centimeter as an add-on supply or material used in conjunction with a primary procedure.
Service type: Wound care supply / biologic matrix application
Typical site of service: Outpatient wound care clinics, physician offices, ambulatory surgical centers, and hospital outpatient departments
Clinical & Coding Specifications
Clinical Context
A patient with a full-thickness skin defect or complex wound on the lower leg following tumor resection presents for reconstruction. The surgical team plans a soft-tissue reconstruction using a myriad matrix biomaterial applied to the wound bed to facilitate dermal regeneration and provide a scaffold for cellular ingrowth. The procedure is billed as an add-on supply per square centimeter using A2032 in addition to the primary operative procedure for wound management or excision. Typical workflow: preoperative assessment and wound measurement, primary procedure such as wide local excision or debridement (primary CPT reported separately), intraoperative measurement of the defect in square centimeters, application and fixation of the myriad matrix material to the prepared wound bed, and standard postoperative wound dressing and monitoring. Usual site of service is an operating room or procedure suite within an outpatient ambulatory surgery center or inpatient hospital setting depending on patient comorbidity and the primary procedure complexity. Typical patient scenario: adult with a large post-excisional defect after removal of a skin malignancy or chronic non-healing ulcer requiring biologic scaffold placement to support dermal regeneration and subsequent grafting or secondary intention healing. Common payors involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |